¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼­¿ï¾Æ»êº´¿ø 24th CARDIOVASCULAR SUMMIT-TCTAP 2019 : 2019-04-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼­¿ï¾Æ»êº´¿ø 24th CARDIOVASCULAR SUMMIT-TCTAP 2019 : 2019-04-29
±³À°ÀÏÀÚ : 2019-04-29
±³À°Àå¼Ò : ÄÚ¿¢½º ÄÁº¥¼Ç ¼¾ÅÍ (ºÏ¹®)  
±³À°ÁÖÁ¦ : 24th CARDIOVASCULAR SUMMIT-TCTAP 2019
ÁÖÃÖ±â°ü : ¼­¿ï¾Æ»êº´¿ø
´ã´çÀÚ : ±èÇöÁ¤
¿¬¶ôó : 02-3010-7255  
À̸ÞÀÏ : secretariat@summitmd.com      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 4000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 9 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í 1. Àü¹®ÀÇ/ÀϹÝÀÇ »çÀüÁ¢¼ö : 120000¿ø/ÇöÀåÁ¢¼ö : 150000¿ø 2. ¼Ò¾Æ½ÉÀåÀÇ »çÀüÁ¢¼ö : 60000¿ø/ÇöÀåÁ¢¼ö : 75000¿ø 3. ÀüÀÓÀÇ/»ê¾÷ü/±âŸ : »çÀüÁ¢¼ö : 70000¿ø/ÇöÀåÁ¢¼ö : 80000¿ø 4. Àü°øÀÇ/°£È£»ç/¹æ»ç¼±»ç/¿µ¾ç»ç/¿îµ¿»ç/ÀÓ»óº´¸®»ç/¹°¸®Ä¡·á»ç/¼±¼öÆ®·¹À̳Ê/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/Çлý »çÀüÁ¢¼ö : 40000¿ø/ÇöÀåÁ¢¼ö : 50000¿ø  ÀºÇà¸í/°èÁ¹øÈ£/¿¹±ÝÁÖ : KEBÇϳªÀºÇà/253-890058-96805/Àç´Ü¹ýÀνÉÀåÇ÷°ü¿¬±¸Àç´Ü      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 07:00~07:08 Durability of TAVR vs. SAVR: Pathology Insights  Renu Virmani(CVPath Institute, Inc., USA) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 07:08~07:16 Durability of TAVR vs. SAVR: Clinical Insights  Hyo-Soo Kim(Seoul National University Hospital, Korea (Republic of)) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 07:16~07:24 Optimal Antithrombotics After TAVR: Ongoing Trials  Duk-Woo Park(Asan Medical Center, Korea (Republic of)) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 07:24~07:32 Cerebral Protection During TAVR: Why and How  Luca Testa(IRCCS San Donato Hospital, Italy) 
Åä·Ð 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 07:32~07:42 Interactive Discussion with Audience Q&A  Jian (James) Ye(St. Paul) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 07:42~07:50 Case 1: TAVR for Pure AR - Indication and Device  Jian (James) Ye(St. Paul) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 07:50~07:58 Case 2: MitraClip for Functional MR - My Best and Worst Cases  Saibal Kar(Cedars Sinai Medical Center, USA) 
Åä·Ð 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 07:58~08:10 Interactive Discussion with Audience Q&A  Jian (James) Ye(St. Paul) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 08:30~08:40 Acute and Mid-term Results of Directional Coronary Atherectomy (DCA) Adjunctive Drug-coated Balloon (DCB) Angioplasty  Tomoko Kobayashi(Kyoto Katsura Hospital, Japan) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 08:40~08:50 Renal Denervation is Effective in Selective Patients with Secondary Causes of Resistant Hypertension  Shu-I Lin(Mackay Memorial Hospital, Taiwan) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 08:50~09:00 Comparison of Crossability Between Two Different Type Scoring Balloons; New Cutting Balloon Wolverine and Lacrosse NSE  Tetsuya Yamamoto(Himeji Cardiovascular Center, Japan) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 09:00~09:10 Study of Three Novel Biomarkers MR-proADM, Midkine and ST2 and Peripheral Atherosclerosis in a Chinese Han Population: A Case-control Study  Lili Zhang(Shanghai Jiao Tong University Affiliated Sixth People) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 09:10~09:20 Mannual Thrombus Aspiration Reduces Myocardial Necrosis During Primary Percutaneous Coronary Intervention (PPCI) in Patients with ST-Elevation Myocardial Infarction (STEMI).  S. Mokaddas Hossain(Labaid Cardiac Hospital, Bangladesh) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 09:20~09:30 Clinical Experience of Percutaneous Coronary Intervention for Severely Calcified Coronary Artery Lesion with Diamondback 360 Coronary Orbital Atherectomy System  Junpei Koike(Kyoto Katsura Hospital, Japan) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 09:30~09:40 Door to Wire Crossing Time and Corrected TIMI Frame Count Local Intracoronary Single Bolus Administration of Thrombolytic Alteplase in Primary PCI in Acute STEMI Within 12 Hours of Symptom Onset  Zulfikri Mukhtar(Adam Malik General Hospital, Indonesia) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 09:40~09:50 Best Abstract Selection & Announcement  Youngkeun Ahn(Chonnam National University Hospital, Korea (Republic of)) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 09:50~10:00 The Era of ¡°Just Stent Them¡± Is Surely Gone.  Vladislav Ertman(Central Clinical Hospital of the Russian Academy of Sciences, Russian Federation) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 10:00~10:10 Impact of Contrast Injection on Intracoronary Pressure During Optical Coherence Tomography Pullback  Kunihiro Shimamura(Wakayama Medical University, Japan) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 10:10~10:20 Long-term Clinical Outcomes in Patients with Untreated Non-culprit Intermediate Coronary Lesion and Evaluation of Predictors by Using Virtual Histology-Intravascular Ultrasound; A Prospective Cohort Study  Young Hoon Seo(Seoul St. Mary) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 10:20~10:30 Contrast Media Induced Hyperemia (Contrast FFR) Compared with Adenosine Induced Hyperemia in the Evaluation of Coronary Fractional Flow Reserve (FFR)  Tanyarat Aramsareewong(Phramongkutklao Hospital, Thailand) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 10:30~10:40 Non-invasive Evaluation of Global and Territorial Coronary Vascular Function: Association with Diastolic Function  Angela S. Koh(National Heart Centre Singapore, Singapore) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 10:40~10:50 The Impact of iFR for Assessing CFR Compared to FFR  Nao Yasuda(Nagoya Ekisaikai Hospital, Japan) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 10:50~11:00 Role of Intra-Vascular Ultrasound in Strategizing and Optimizing Bifurcation Stenting  Debdatta Bhattacharyya(NH-RTIICS, India) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 11:00~11:10 Best Abstract Selection & Announcement  William F. Fearon(Stanford University School of Medicine, USA) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 11:10~11:20 Prognostic Significance of Reperfusion Delays in Patients Presenting for ST-elevation Myocardial Infarction in the Tunisian Context  Walid Jomaa(Fattouma Bourguiba University Hospital, Tunisia) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 11:20~11:30 Clinical Characteristics and Outcomes of Young and Old Patients with Coronary Artery Disease in Second and Third Generation Drug Eluting Stent Era  Koyama Takafumi(Shounan Fujisawa Tokushukai, Japan) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 11:30~11:40 Symptom-to-Balloon Time and Myocardial Blush Grade Are Predictors of Left Ventricular Remodelling After Successful Primary Percutaneous Coronary Intervention  El Sayed Farag(Zagazig University, Egypt) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 11:40~11:50 Association of Vitamin D Level with Severity of Angiographically Documented Coronary Artery Disease: Observations from Bangladeshi Patients  Ashraf Ur Rahman(National Institute of Cardiovascular Diseases (NICVD), Bangladesh) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 11:50~12:00 Door to Balloon Time and Causes of Delay of Primary Percutaneous Coronary Intervention in Acute ST Elevation Myocardial Infarction Patients – A Single Center Prospective Study  Anurag Jain(Sagarshree Super Speciality Hospital, India) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 12:00~12:10 Early Invasive Versus Conservative Treatment Strategies in Octogenarians with Acute Coronary Syndrome: One-year Clinical Outcome, a Single Centre Experience  Vipin Mughilassery Thomachan(Al Ain Hospital, United Arab Emirates) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 12:10~12:20 Predictors of In-hospital Mortality in Patients Presenting with Acute Coronary Syndromes  Fathima Aaysha Cader(Ibrahim Cardiac Hospital & Research Institute, Bangladesh) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 12:20~12:30 Best Abstract Selection & Announcement  Shunichi Miyazaki(Kinki University Hospital, Japan) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 14:00~14:08 TAVR: Long Journey from Concept to Human  Alain G. Cribier(Hospital Charles Nicolle, France) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 14:08~14:16 TAVR in Low-risk Patients: Insights from PARTNER-3 and Evolut R Low-risk Trial  Martin Bert Leon(New York-Presbyterian Hospital, Columbia University Medical Center, USA) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 14:16~14:24 TAVR in 2019: Appropriate Patient and Device Selection  Eberhard Grube(University Hospital, Bonn, Germany) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 14:24~14:32 Expanding Indication of TAVR: Ongoing Trials and Expectations  Alan C. Yeung(Stanford University School of Medicine, USA) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 14:32~14:40 Pharmacotherapy After TAVR: Antiplatelet or Anticoagulation Therapy  Raj Makkar(Cedars-Sinai Medical Center, USA) 
Åä·Ð 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 14:40~14:46 Interactive Discussion with Audience Q&A  Alain G. Cribier(Hospital Charles Nicolle, France) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 14:46~14:54 The MITRA-FR Trial: Why the Trial Fails?  Thierry Lefevre(Institut Hospitalier Jacques Cartier, France) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 14:54~15:02 The REDUCE-FMR Trial  Horst Sievert(CardioVascular Center Frankfurt CVC, Germany) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 15:02~15:10 The COAPT Trial: How the Trial Succeed?  Gregg W. Stone(Columbia University Medical Center/ Cardiovascular Research Foundation, USA) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 15:10~15:18 QOL Outcomes of the COAPT Trial  David J. Cohen(Saint Luke) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 15:18~15:26 MitraClip for Function MR: How Can We Get COAPT Results?  Saibal Kar(Cedars Sinai Medical Center, USA) 
Åä·Ð 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 15:26~15:32 Interactive Discussion with Audience Q&A  Alain G. Cribier(Hospital Charles Nicolle, France) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 15:32~15:40 Mitral Valve-in-Valve and Valve-in-Ring: Outcomes and Procedural Considerations  Raj Makkar(Cedars-Sinai Medical Center, USA) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 15:40~15:48 Transcatheter Mitral Valve Replacement: Current Evidence and Experience  Jian (James) Ye(St. Paul) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 15:48~15:56 Toolbox for Transcatheter Tricuspid Valve Therapy  Vinayak Bapat(Columbia University Medical Center, USA) 
Åä·Ð 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 15:56~16:00 Interactive Discussion with Audience Q&A  Alain G. Cribier(Hospital Charles Nicolle, France) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 16:00~16:08 The Clinical Value of IVUS: Data and its Application in Cath Lab  Myeong-Ki Hong(Severance Hospital, Korea (Republic of)) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 16:08~16:16 The Clinical Value of OCT: European Consensus Document  Evelyn Regar(University Hospital Zurich, Germany) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 16:16~16:24 Imaging DIY: Imaging-Trained Operator Can Make a Good Clinical Outcome  Gary S. Mintz(Cardiovascular Research Foundation, USA) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 16:24~16:32 [Case-based Debate: Intracoronary Imaging Modalities for PCI Guidance] IVUS Is Better!  Jung-Min Ahn(Asan Medical Center, Korea (Republic of)) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 16:32~16:40 [Case-based Debate: Intracoronary Imaging Modalities for PCI Guidance] OCT Is Better!  Takashi Kubo(Wakayama Medical University, Japan) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 16:40~16:48 OCT Versus IVUS for Guiding PCI: Current Evidences and Ongoing OCTIVUS Trial  Duk-Woo Park(Asan Medical Center, Korea (Republic of)) 
Åä·Ð 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 16:48~17:00 Interactive Discussion with Audience Q&A  Seung-Jung Park(Asan Medical Center, Korea (Republic of)) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 17:00~17:08 Change of Practices and Long-Term Outcomes After Systematic Use of Coronary  Seung-Jung Park(Asan Medical Center, Korea (Republic of)) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 17:08~17:16 Coronary Psychology: Why Don  Nils Johnson(McGovern Medical School at UTHealth, USA) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 17:16~17:24 2 Year Outcomes of iFR Randomized Trial: DEFINE FLARE and SWEDEHEART Studies  Javier Escaned(Hospital Clinico San Carlos, Spain) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 17:24~17:32 Prognosis of Discordant Lesion Between FFR and Hyperemia Free Indexes  Jung-Min Ahn(Asan Medical Center, Korea (Republic of)) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 17:32~17:40 The ADVANCE of FFR-CT for PRECISE DECISION  Gregg W. Stone(Columbia University Medical Center/ Cardiovascular Research Foundation, USA) 
±³À°½Ã°£ 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 17:40~17:48 Can FAST-FFR Change Our Cath Lab Practice  William F. Fearon(Stanford University School of Medicine, USA) 
Åä·Ð 04-29 ÄÚ¿¢½º ÄÁº¥¼Ç¼¾ÅÍ 17:48~18:00 Interactive Discussion with Audience Q&A  Seung-Jung Park(Asan Medical Center, Korea (Republic of)) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼­¿ï¾Æ»êº´¿ø 24th CARDIOVASCULAR SUMMIT-TCTAP 2019 : 2019-04-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÀÌõ½ÃÀÇ»çȸ ½É¹æ¼¼µ¿ Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2019-03-28
´ÙÀ½±Û ¼­¿ï¾Æ»êº´¿ø 24th CARDIOVASCULAR SUMMIT-TCTAP 2019 : 2019-04-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20467 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31 0 19 2024-04-17
20466 °æ±â ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30 0 6 2024-04-17
20465 ¼­¿ï Á¦20Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ ÇÁ·Î±×·¥ : 2024-05-26 0 15 2024-04-17
20464 °æ±â 2024³â Á¦86Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-26 0 7 2024-04-17
20463 ¼­¿ï 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-26 0 6 2024-04-17
20462 ¼­¿ï ´ëÇÑÃæ°ÝÆÄÄ¡·áÇÐȸ 2024 Ãá°è Çмú´ëȸ : 2024-05-26 0 10 2024-04-17
20461 ¼­¿ï Áø´Ü ü°èÀû¹®Çå°íÂû ¿öÅ©¼¥ : 2024-05-25 0 12 2024-04-17
20460 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦17ȸ ODOT (One Day Course of Obesity Treatment) : 2024-05-25 0 8 2024-04-17
20459 ¼­¿ï 2024³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-05-24 0 5 2024-04-17
20458 ¼­¿ï 2024 Á¦12ȸ ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-24 0 9 2024-04-17
20457 ¼­¿ï 2024³â ¿µµîÆ÷±¸ÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-05-21 0 8 2024-04-17
20456 ¼­¿ï 2024³â ´ëÇÑÀÓ»ó°Ç°­ÁõÁøÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-19 0 11 2024-04-17
20455 ¼­¿ï Á¦7Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 4 2024-04-17
20454 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°­Á : 2024-05-18 0 6 2024-04-17
20453 ¼­¿ï 2024³â ´ëÇÑ¿¬ÇÏÀå¾ÖÇÐȸ Á¦14ȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 4 2024-04-17
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷